Health Care Roundup: Market Talk

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0922 ET – Evotec’s profit warning this week exposed the extent to which the German drug-discovery company relies on contracts yet to be signed, which makes its future prospects uncertain, Berenberg analysts say in a research note. The guidance reset is a setback that pushes Evotec’s near-term visibility to an all-time low, according to Berenberg. “It is highly surprising to see the sheer scope of uncontracted strategic partnerships, both old and new, and high-margin milestone assumptions that were originally baked into the FY 2026 outlook—in contrast to prior earnings call comments,” the analysts say. Berenberg cuts its stock recommendation on Evotec to hold from buy, and slashes its target price to 3.60 euros from 9.40 euros. Shares fall 1.3% to 3.46 euros. (adria.calatayud@wsj.com)